Recent layoff pushed many productive people out, but mediocre and connected are still with the company, for example, those doing standard low level analytical procedures that could easily be outsourced. Worse, some newcomers used the reorganization to dismantle organization structures and bring their own cronies in. Those newcomers could not match the quality of people who were pushed out 2 years ago, since they were failures in their earlier careers for years doing marginal work in well known biotechnology companies, such like Amgen or Merck. They would never hire people better than themselves. A downward spiral.
Sad decline of Genentech
https://www.fiercebiotech.com/biotech/genentech-shut-down-cancer-immunology-department-amid-broader-downsizing-efforts?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech+Tracker
